- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT04340843
Testen van de combinatie van Belinostat en SGI-110 (Guadecitabine) of ASTX727 voor de behandeling van inoperabel en gemetastaseerd conventioneel chondrosarcoom
Een fase 2-studie van Belinostat en SGI-110 (Guadecitabine) of ASTX727 voor de behandeling van inoperabel en gemetastaseerd conventioneel chondrosarcoom
This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) or ASTX727 in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread from where it first started (primary site) to other places in the body (metastatic). Belinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as guadecitabine and ASTX727, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving belinostat in combination with guadecitabine or ASTX727 may lower the chance of unresectable and metastatic chondrosarcoma growing or spreading.
Studie Overzicht
Toestand
Conditie
Gedetailleerde beschrijving
PRIMARY OBJECTIVE:
I. To conduct a phase 2 clinical trial to evaluate whether combination treatment with belinostat and decitabine and cedazuridine (ASTX727) shows preliminary evidence of clinical activity in unresectable or metastatic conventional chondrosarcoma (CS) using an objective response rate endpoint.
SECONDARY OBJECTIVES:
I. To evaluate the toxicity profile associated with the belinostat and ASTX727. II. To evaluate the progression free survival (PFS) associated with the belinostat and ASTX727.
III. To evaluate the toxicity profile, objective response rate and progression free survival among the initial six patients treated with belinostat and SGI-110 (guadecitabine) prior to Amendment 5 in which ASTX727 was substituted for SGI-110 (guadecitabine).
CORRELATIVE OBJECTIVES:
I. To determine the IDH1/2 mutational status of subject's tumors and to evaluate for a relationship between presence of IDH1/2 mutation and clinical benefit from study treatment.
II. To conduct ribonucleic acid sequencing (RNAseq) analysis using baseline and on-treatment tissue biopsies to study the effects of study treatment on CS gene expression patterns and identify candidate genes which may underlie treatment efficacy.
III. To evaluate for changes in global deoxyribonucleic acid (DNA) methylation levels using baseline and on-treatment biopsies and correlate changes in global methylation with clinical benefit from study treatment.
IV. To use multiplex immunohistochemistry to interrogate the immune microenvironment in baseline and on-treatment tissue biopsies to define changes in infiltrating immune cell subsets and PD-L1/major histocompatibility complex (MHC) expression by immune and tumor cells associated with study treatment.
OUTLINE:
Patients receive guadecitabine subcutaneously (SC) or ASTX727 orally (PO) on days 1-5. Patients also receive belinostat intravenously (IV) over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood during screening, tumor biopsy during screening and on study, and magnetic resonance imaging (MRI) or computed tomography (CT) throughout the trial.
After completion of study treatment, patients are followed up every 3 months for 24 months.
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 2
Contacten en locaties
Studie Locaties
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85054
- Mayo Clinic Hospital in Arizona
-
-
California
-
Duarte, California, Verenigde Staten, 91010
- City of Hope Comprehensive Cancer Center
-
Los Angeles, California, Verenigde Staten, 90033
- USC / Norris Comprehensive Cancer Center
-
Los Angeles, California, Verenigde Staten, 90033
- Los Angeles General Medical Center
-
Newport Beach, California, Verenigde Staten, 92663
- USC Norris Oncology/Hematology-Newport Beach
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- UCHealth University of Colorado Hospital
-
-
Connecticut
-
New Haven, Connecticut, Verenigde Staten, 06520
- Yale University
-
-
Florida
-
Coral Gables, Florida, Verenigde Staten, 33146
- UM Sylvester Comprehensive Cancer Center at Coral Gables
-
Deerfield Beach, Florida, Verenigde Staten, 33442
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach
-
Jacksonville, Florida, Verenigde Staten, 32224-9980
- Mayo Clinic in Florida
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Plantation, Florida, Verenigde Staten, 33324
- UM Sylvester Comprehensive Cancer Center at Plantation
-
Tampa, Florida, Verenigde Staten, 33612
- Moffitt Cancer Center
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Northwestern University
-
-
Kansas
-
Hays, Kansas, Verenigde Staten, 67601
- HaysMed
-
Kansas City, Kansas, Verenigde Staten, 66160
- University of Kansas Cancer Center
-
Lawrence, Kansas, Verenigde Staten, 66044
- Lawrence Memorial Hospital
-
Overland Park, Kansas, Verenigde Staten, 66210
- University of Kansas Cancer Center-Overland Park
-
Pittsburg, Kansas, Verenigde Staten, 66762
- Mercy Hospital Pittsburg
-
Salina, Kansas, Verenigde Staten, 67401
- Salina Regional Health Center
-
Topeka, Kansas, Verenigde Staten, 66606
- University of Kansas Health System Saint Francis Campus
-
Westwood, Kansas, Verenigde Staten, 66205
- University of Kansas Hospital-Westwood Cancer Center
-
-
Minnesota
-
Rochester, Minnesota, Verenigde Staten, 55905
- Mayo Clinic in Rochester
-
-
Missouri
-
Creve Coeur, Missouri, Verenigde Staten, 63141
- Siteman Cancer Center at West County Hospital
-
Kansas City, Missouri, Verenigde Staten, 64154
- University of Kansas Cancer Center - North
-
Kansas City, Missouri, Verenigde Staten, 64108
- University Health Truman Medical Center
-
Lee's Summit, Missouri, Verenigde Staten, 64064
- University of Kansas Cancer Center - Lee's Summit
-
North Kansas City, Missouri, Verenigde Staten, 64116
- University of Kansas Cancer Center at North Kansas City Hospital
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Verenigde Staten, 63129
- Siteman Cancer Center-South County
-
-
New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Verenigde Staten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43210
- Ohio State University Comprehensive Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19107
- Thomas Jefferson University Hospital
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15232
- UPMC Hillman Cancer Center
-
-
Texas
-
Houston, Texas, Verenigde Staten, 77030
- UT MD Anderson Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84112
- Huntsman Cancer Institute/University of Utah
-
-
Virginia
-
Richmond, Virginia, Verenigde Staten, 23298
- VCU Massey Comprehensive Cancer Center
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Patients must have biopsy-proven conventional chondrosarcoma (CS) which is:
-
Either metastatic or locally advanced and unresectable, and
-
Measurable at study entry according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 criteria, and
-
Amenable to biopsy with imaging guidance at no or acceptable risk to the patient as defined by institutional guidelines for research-related biopsies or the treating investigator's assessment
-
In addition, the following criteria must be met:
- Patients must have at least one lesion measurable by RECIST version 1.1 criteria which has not been previously irradiated
- Patients who have histologic evidence of grade 1 chondrosarcoma only must either be symptomatic from their disease in the opinion of the treating investigator or demonstrate radiographic evidence of disease progression in the 3 months prior to initiation of study treatment
-
Note: Pathology review and confirmation of diagnosis will occur at the site enrolling the patient on this study
-
-
Patients may have been treated with any number of prior systemic therapies. Because there are no Food and Drug Administration (FDA)-approved treatments for this disease, patients who have received no prior systemic therapy are also eligible. However, disease must be deemed surgically unresectable
-
Age >= 18 years. Chondrosarcoma is rarely encountered in children and adolescents
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
-
Absolute neutrophil count >= 1,000/mm^3
-
Hemoglobin 8 g/dL
-
Platelet count >= 75,000/mm^3
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2 x institutional ULN
-
Creatinine =< 1.5 x institutional ULN OR glomerular filtration rate (GFR) >= 45 mL/min/1.73 m^2
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression, if patients have been clinically asymptomatic, and if patients have not received systemic corticosteroids for at least 28 days. Patients with brain metastases not meeting these criteria are not eligible
-
Patients must be disease-free of prior invasive malignancies for > 5 years, with the exception of curatively-treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.
- NOTE: If there is a history of prior malignancy, patients must not be receiving other specific treatment for that cancer
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
The effects of belinostat and SGI-110 (guadecitabine) or ASTX727 on the developing human fetus are unknown. For this reason, and because the DNA methyltransferase inhibitor decitabine, the active metabolite of SGI-110 (guadecitabine) and a component of ASTX727, is known to be teratogenic, and because belinostat may cause teratogenicity and/or embryo-fetal lethality by virtue of targeting actively dividing cells, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for at least 6 months after the last dose of study drugs. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 3 months after completion of belinostat and SGI-110 (guadecitabine) or ASTX727 administration
-
Patients must be able to understand and willing to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
-
Patients with dedifferentiated, mesenchymal, or clear cell chondrosarcoma are not eligible
-
Patients who have not recovered from adverse events (AEs) (i.e., have residual toxicities > grade 1) due to prior anti-cancer therapy are not allowed, with the exceptions of alopecia and endocrinopathies from prior immunotherapy-based treatments that are well-controlled with hormone replacement. In addition, the following time periods must elapse between the last dose of prior anti-cancer treatment and initiation of study treatment on this protocol:
- Cytotoxic chemotherapy or biologic, including immunotherapy: 28 days
- Small molecule targeted drug: 21 days or 5 half-lives, whichever is shorter. If 5 half-lives is shorter than 21 days, then 21 days applies.
- Radiation: 28 days, except for palliative radiation, for which 14 days applies
-
Patients who are receiving any other investigational agents
-
Patients with known history of allergic reactions or sensitivity attributed to compounds of similar chemical or biologic composition to SGI-110 (guadecitabine), its active metabolite decitabine, or ASTX727, or belinostat
-
Chronic use of any medications or substances that are strong inhibitors of UGT1A1 is not allowed. Patients must switch to alternative medications 7-14 days before treatment with belinostat. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
-
Patients with any known UGT1A1 polymorphism, heterozygous or homozygous, associated with reduced function (UGT1A1*6, UGT1A1*28, or UGT1A1*60)
-
Patients with uncontrolled intercurrent illness
-
Patients with psychiatric illness/social situations that would limit compliance with study requirements
-
Pregnant women are excluded from this study because SGI-110 (guadecitabine) is a derivative of decitabine, and ASTX727 contains the agent decitabine, which has the potential for teratogenic or abortifacient effects, and because belinostat may cause teratogenicity and/or embryo-fetal lethality by virtue of targeting actively dividing cells. Because there is an unknown but potential risk for AEs in nursing infants secondary to treatment of the mother with SGI-110 (guadecitabine), ASTX727 and belinostat, breastfeeding should be discontinued
-
Prolongation of the heart-rate corrected QT (QTc) interval >= 450 ms (i.e., grade 1 or higher) on the screening electrocardiogram (ECG) prior to initiation of study treatment. If baseline QTc on screening ECG is >= 450 ms (i.e., grade 1 or higher):
- Check potassium and magnesium serum levels, and
- Correct any identified hypokalemia and/or hypomagnesemia and repeat ECG to confirm a QTc interval < 450 ms
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment (belinostat, guadecitabine, ASTX727)
Patients receive guadecitabine SC or ASTX727 PO on days 1-5. Patients also receive belinostat IV over 30 minutes on days 1-5. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo collection of blood during screening, tumor biopsy during screening and on study, and MRI or CT throughout the trial. |
Undergo CT
Andere namen:
Undergo MRI
Andere namen:
Undergo biopsy
Andere namen:
Undergo collection of blood
Andere namen:
Given PO
Andere namen:
Given IV
Andere namen:
Given SC
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Objective Response Rate (ORR) in Belinostat, ASTX727
Tijdsspanne: Within 6 months after initiating study treatment
|
Best Objective Response per RECIST Version 1.1 criteria. CR, complete response defined by the disappearance of all target lesions; PR, partial response defined by at least a 30% decrease in the sum of the diameters of target lesions; SD, stable disease defined by neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease; PD, progressive disease defined by at least a 20% increase in the sum of the diameters of target lesions or the appearance of one or more new lesions. |
Within 6 months after initiating study treatment
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Presence of Treatment Related Adverse Events (AEs) in Belinostat, ASTX727
Tijdsspanne: Up to 24 months post treatment
|
Adverse events (AEs) in belinostat, ASTX727 were recorded at each clinical visit and were categorized according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The attribution of AEs to each of the study drugs was recorded and categorized as possibly, probably, or definitely related to treatment. AEs are reported as counts and percentages per AE by grade and the number of patients with a given maximal grade of toxicity. |
Up to 24 months post treatment
|
|
Progression Free Survival (PFS) in Belinostat, ASTX727
Tijdsspanne: Time from first treatment with the study drug to the earliest of either disease progression or death from any cause, assessed up to 24 months.
|
PFS is defined as the time from first treatment with the study drug to the earliest of either disease progression or death from any cause. Patients who are alive and progression free will be censored at the time of their last follow-up. The Kaplan-Meier method was used to evaluate time to event endpoints. Median PFS was reported with a 95% confidence interval. Data will be presented as Kaplan Meier plots. |
Time from first treatment with the study drug to the earliest of either disease progression or death from any cause, assessed up to 24 months.
|
|
Presence of Treatment Related Adverse Events (AEs) in Belinostat, SGI-110
Tijdsspanne: Up to 24 months post treatment
|
Adverse events (AEs) from belinostat, SGI-110 were recorded at each clinical visit and were categorized according to National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. The attribution of AEs to each of the study drugs was recorded and categorized as possibly, probably, or definitely related to treatment. AEs are reported as counts and percentages per AE by grade and the number of patients with a given maximal grade of toxicity. |
Up to 24 months post treatment
|
|
Progression Free Survival (PFS) in Belinostat, SGI-110
Tijdsspanne: Time from first treatment with the study drug to the earliest of either disease progression or death from any cause, assessed up to 24 months.
|
PFS is defined as the time from first treatment with the study drug to the earliest of either disease progression or death from any cause. Patients who are alive and progression free will be censored at the time of their last follow-up. The Kaplan-Meier method was used to evaluate time to event endpoints. Median PFS was reported with a 95% confidence interval. Data will be presented as Kaplan Meier plots. |
Time from first treatment with the study drug to the earliest of either disease progression or death from any cause, assessed up to 24 months.
|
|
Objective Response Rate (ORR) in Belinostat, SGI-110
Tijdsspanne: Within 6 months after initiating study treatment.
|
Best Objective Response per RECIST Version 1.1 criteria. CR, complete response defined by the disappearance of all target lesions; PR, partial response defined by at least a 30% decrease in the sum of the diameters of target lesions; SD, stable disease defined by neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease; PD, progressive disease defined by at least a 20% increase in the sum of the diameters of target lesions or the appearance of one or more new lesions. |
Within 6 months after initiating study treatment.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
IDH1/2 Mutational Status
Tijdsspanne: Up to 24 months post treatment
|
Will compare the difference in the objective response rate among patients with IDH1/2 mutations as compared those without IDH1/2 mutations using Fisher's exact test. |
Up to 24 months post treatment
|
|
Changes in Expression of Conventional Chondrosarcoma Genes
Tijdsspanne: Baseline up to 24 months post treatment
|
Data from ribonucleic acid sequencing will be analyzed. Differential expression profiles between baseline and on-treatment samples will be analyzed at the gene level and gene expression changes defined as significant based on absolute log2 fold changes > 2 and adjusted p values < 0.005 for each comparison with consideration of the false discovery rate. |
Baseline up to 24 months post treatment
|
|
Changes in Global Deoxyribonucleic Acid Methylation
Tijdsspanne: Baseline up to 24 months post treatment
|
A Wilcoxon signed-rank test with continuity correction will be used to calculate P values for comparing methylation level distribution at the different time points. |
Baseline up to 24 months post treatment
|
|
Changes in Tumor Microenvironment
Tijdsspanne: Baseline up to 24 months post treatment
|
For quantitative immune multiplexing, data is derived from inForm software, and changes in defined immune cell subsets and expression between baseline and on-treatment samples will be assessed using paired T-tests. |
Baseline up to 24 months post treatment
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Mia Weiss, Yale University Cancer Center LAO
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Onderzoekstechnieken
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Chirurgische procedures, operatief
- Cytologische technieken
- Cytodiagnose
- Diagnostische technieken, chirurgisch
- Chemie -technieken, analytisch
- Spectrumanalyse
- Biopsie
- Exemplaarbehandeling
- Magnetische resonantiespectroscopie
- belinostat
- Decitabine en combinatie van cedazuridine
- guadecitabine
Andere studie-ID-nummers
- NCI-2020-02187
- UM1CA186686 (Subsidie/contract van de Amerikaanse NIH)
- 10330 (Andere identificatie: CTEP)
- NCI-2020-02187 (Register-ID: CTRP (Clinical Trial Reporting Program))
- 10330 (Andere identificatie: Yale University Cancer Center LAO)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .